{"title":"人工虹膜植入术的安全性和有效性初步评价。","authors":"Si-Yi Wang, Mi-Mi Liu, Xi-Le Li, Chao-Xiang Ge, Wei Chen, Zhen-Quan Zhao","doi":"10.18240/ijo.2025.08.08","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To preliminary explore the safety and effectiveness of artificial iris implantation.</p><p><strong>Methods: </strong>Fourteen patients with iris defects who underwent artificial iris implantation at Hainan Boao Super Hospital from June 2020 to September 2021 were retrospectively analyzed for safety and effectiveness of the surgery by comparing the preoperative and postoperative best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal endothelial cell density (ECD), ocular axial length (AL), anterior chamber depth (ACD), patient satisfaction of photophobia and appearance improvement, and postoperative complications.</p><p><strong>Results: </strong>The mean age was 37.21±14.85 (7-60)y, including 13 males and 1 female. The mean follow-up period was 4.64±2.32 (1-10)mo. The mean AL was 24.00±1.06 (21.68-25.58) mm. The postoperative mean anterior chamber depth measured was 4.07±0.75 (2.61-5.07) mm. The mean BCVA was 0.69±0.65 logMAR preoperatively and 0.46±0.60 logMAR at the last follow-up time (<i>P</i>=0.36). There was no significant differences in the IOP preoperative and postoperative (14.14±3.10 and 13.65±3.08 mm Hg, respectively, <i>P</i>=0.69). The preoperative ECD was 1674.09±566.11 per 1 mm<sup>2</sup>, and the postoperative ECD was 1439.45±425.15 per 1 mm<sup>2</sup> (<i>P</i>=0.21). No obvious corneal opacity or corneal decompensation was observed in all patients. The preoperative and postoperative photophobia scores were 8.50±1.55 and 4.50±1.94, respectively (<i>P</i><0.05), and the preoperative and postoperative appearance defect scores were 6.58±2.98 and 2.75±1.69, respectively (<i>P</i><0.05). Among the 14 patients, one had artificial iris displacement, two had a transient IOP rise after treatment of antiglaucomatous eyedrops. No complications were observed during surgery.</p><p><strong>Conclusion: </strong>The novel artificial iris material is safe, which can significantly improve the appearance defects and photophobia, improve the postoperative visual acuity to a certain extent. This surgery had a high patient satisfaction rate with few and controllable postoperative complications. At the same time, the artificial iris, with its diverse configurations, variable colors, arbitrary cutting, and various surgical procedures, fully realizes personalized treatment, which solves the clinical problem of iris defect.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 8","pages":"1478-1483"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12311453/pdf/","citationCount":"0","resultStr":"{\"title\":\"Preliminary assessment of the safety and effectiveness of artificial iris implantation.\",\"authors\":\"Si-Yi Wang, Mi-Mi Liu, Xi-Le Li, Chao-Xiang Ge, Wei Chen, Zhen-Quan Zhao\",\"doi\":\"10.18240/ijo.2025.08.08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To preliminary explore the safety and effectiveness of artificial iris implantation.</p><p><strong>Methods: </strong>Fourteen patients with iris defects who underwent artificial iris implantation at Hainan Boao Super Hospital from June 2020 to September 2021 were retrospectively analyzed for safety and effectiveness of the surgery by comparing the preoperative and postoperative best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal endothelial cell density (ECD), ocular axial length (AL), anterior chamber depth (ACD), patient satisfaction of photophobia and appearance improvement, and postoperative complications.</p><p><strong>Results: </strong>The mean age was 37.21±14.85 (7-60)y, including 13 males and 1 female. The mean follow-up period was 4.64±2.32 (1-10)mo. The mean AL was 24.00±1.06 (21.68-25.58) mm. The postoperative mean anterior chamber depth measured was 4.07±0.75 (2.61-5.07) mm. The mean BCVA was 0.69±0.65 logMAR preoperatively and 0.46±0.60 logMAR at the last follow-up time (<i>P</i>=0.36). There was no significant differences in the IOP preoperative and postoperative (14.14±3.10 and 13.65±3.08 mm Hg, respectively, <i>P</i>=0.69). The preoperative ECD was 1674.09±566.11 per 1 mm<sup>2</sup>, and the postoperative ECD was 1439.45±425.15 per 1 mm<sup>2</sup> (<i>P</i>=0.21). No obvious corneal opacity or corneal decompensation was observed in all patients. The preoperative and postoperative photophobia scores were 8.50±1.55 and 4.50±1.94, respectively (<i>P</i><0.05), and the preoperative and postoperative appearance defect scores were 6.58±2.98 and 2.75±1.69, respectively (<i>P</i><0.05). Among the 14 patients, one had artificial iris displacement, two had a transient IOP rise after treatment of antiglaucomatous eyedrops. No complications were observed during surgery.</p><p><strong>Conclusion: </strong>The novel artificial iris material is safe, which can significantly improve the appearance defects and photophobia, improve the postoperative visual acuity to a certain extent. This surgery had a high patient satisfaction rate with few and controllable postoperative complications. At the same time, the artificial iris, with its diverse configurations, variable colors, arbitrary cutting, and various surgical procedures, fully realizes personalized treatment, which solves the clinical problem of iris defect.</p>\",\"PeriodicalId\":14312,\"journal\":{\"name\":\"International journal of ophthalmology\",\"volume\":\"18 8\",\"pages\":\"1478-1483\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12311453/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18240/ijo.2025.08.08\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.08.08","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Preliminary assessment of the safety and effectiveness of artificial iris implantation.
Aim: To preliminary explore the safety and effectiveness of artificial iris implantation.
Methods: Fourteen patients with iris defects who underwent artificial iris implantation at Hainan Boao Super Hospital from June 2020 to September 2021 were retrospectively analyzed for safety and effectiveness of the surgery by comparing the preoperative and postoperative best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal endothelial cell density (ECD), ocular axial length (AL), anterior chamber depth (ACD), patient satisfaction of photophobia and appearance improvement, and postoperative complications.
Results: The mean age was 37.21±14.85 (7-60)y, including 13 males and 1 female. The mean follow-up period was 4.64±2.32 (1-10)mo. The mean AL was 24.00±1.06 (21.68-25.58) mm. The postoperative mean anterior chamber depth measured was 4.07±0.75 (2.61-5.07) mm. The mean BCVA was 0.69±0.65 logMAR preoperatively and 0.46±0.60 logMAR at the last follow-up time (P=0.36). There was no significant differences in the IOP preoperative and postoperative (14.14±3.10 and 13.65±3.08 mm Hg, respectively, P=0.69). The preoperative ECD was 1674.09±566.11 per 1 mm2, and the postoperative ECD was 1439.45±425.15 per 1 mm2 (P=0.21). No obvious corneal opacity or corneal decompensation was observed in all patients. The preoperative and postoperative photophobia scores were 8.50±1.55 and 4.50±1.94, respectively (P<0.05), and the preoperative and postoperative appearance defect scores were 6.58±2.98 and 2.75±1.69, respectively (P<0.05). Among the 14 patients, one had artificial iris displacement, two had a transient IOP rise after treatment of antiglaucomatous eyedrops. No complications were observed during surgery.
Conclusion: The novel artificial iris material is safe, which can significantly improve the appearance defects and photophobia, improve the postoperative visual acuity to a certain extent. This surgery had a high patient satisfaction rate with few and controllable postoperative complications. At the same time, the artificial iris, with its diverse configurations, variable colors, arbitrary cutting, and various surgical procedures, fully realizes personalized treatment, which solves the clinical problem of iris defect.
期刊介绍：
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
